Gene Editing Stocks Surge... Beam Therapeutics Market Cap Increases by 390 Billion Won in One Day

Beam Therapeutics Inc. (NASDAQ: BEAM) shares closed at $29.40 on the Nasdaq on April 26, up 8.45%. Trading volume surged to approximately 2.11 million shares, well above its average, and the company’s market capitalization expanded to roughly $3 billion (about KRW 4.2 trillion). In just one day, market cap rose by about $280 million (approximately KRW 390 billion).

Recently, Beam Therapeutics announced that its alpha-1 antitrypsin deficiency (AATD) therapy candidate BEAM-302 demonstrated a meaningful protein‐correction effect in early clinical trials and that it has reached agreement with the U.S. Food and Drug Administration on an accelerated approval pathway for the program. Earlier this month, a disclosure revealed that CEO John Evans sold over 30,000 shares of company stock, creating a short-term shift in supply and demand.

Beam Therapeutics is a U.S. biotech company developing gene therapies using base‐editing technology, with a pipeline targeting rare genetic disorders such as sickle cell disease and AATD. In 2025, a global licensing option was exercised under its collaboration with Pfizer for a liver-targeted candidate. This year, the company further accelerated its platform expansion by unveiling a liver disease program for phenylketonuria (PKU), designated BEAM-304.